Post-Kala-azar Dermal Leishmaniasis (PKDL)
What is Post-Kala-azar Dermal Leishmaniasis (PKDL)?
Post-kala-azar dermal leishmaniasis, known as PKDL, is a skin condition that can develop after treatment for visceral leishmaniasis. Visceral leishmaniasis is a serious parasitic infection that affects internal organs like the spleen and liver. PKDL appears as skin changes, including rashes or patches of lighter or darker skin.
This condition occurs when Leishmania parasites persist in the skin after the internal infection has been treated. PKDL can develop months or even years after successful treatment of visceral leishmaniasis. The skin changes usually appear on the face, arms, trunk, and other parts of the body.
PKDL is most common in East Africa and the Indian subcontinent, where visceral leishmaniasis is endemic. People who had visceral leishmaniasis in these regions face higher risk of developing this skin complication. Understanding PKDL helps patients recognize symptoms early and seek appropriate care.
Symptoms
- Rash or skin patches that may be raised or flat
- Areas of skin that appear lighter than surrounding skin
- Areas of skin that appear darker than surrounding skin
- Skin changes typically on the face, especially around the mouth and nose
- Patches on the arms, trunk, or other body areas
- Skin lesions that develop slowly over time
- Small bumps or nodules on the skin
- Skin changes that do not cause pain or itching
Many people with PKDL do not experience discomfort from the skin changes. The condition primarily affects appearance rather than causing physical symptoms like pain or fever. Some patients may not notice early changes until the skin patches become more visible.
Concerned about Post-Kala-azar Dermal Leishmaniasis (PKDL)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
PKDL develops when Leishmania parasites remain in the skin after visceral leishmaniasis treatment. The parasites are spread through the bite of infected sandflies found in certain tropical and subtropical regions. After treatment for the internal infection, some parasites can survive in skin tissue and cause this secondary condition.
Risk factors include a history of visceral leishmaniasis, living in or traveling to endemic areas, and the specific Leishmania species involved. People from East Africa and the Indian subcontinent face higher risk. The condition can appear anywhere from several months to several years after completing visceral leishmaniasis treatment. Weakened immune function may also play a role in parasite persistence.
How it's diagnosed
Diagnosing PKDL requires evaluation by a doctor familiar with parasitic infections. Healthcare providers examine the skin changes and review medical history, especially past visceral leishmaniasis treatment. Blood tests can detect antibodies to Leishmania parasites, showing evidence of current or past infection.
Skin samples may be taken from affected areas to look for parasites under a microscope. This helps confirm the diagnosis and rule out other skin conditions. Specialized testing beyond routine blood work is often needed for accurate diagnosis. Talk to a doctor about appropriate testing if you have skin changes after visceral leishmaniasis treatment.
Treatment options
- Antiparasitic medications specific to Leishmania infections
- Extended treatment courses, often lasting several weeks to months
- Close monitoring by infectious disease specialists
- Skin care to protect affected areas from sun exposure
- Nutritional support to strengthen immune function
- Regular follow-up visits to track treatment response
- Combination therapies for more severe cases
- Lifestyle adjustments to support healing and prevent complications
Frequently asked questions
PKDL is a skin condition that can develop after treatment for visceral leishmaniasis, a parasitic infection. It causes skin changes like rashes or patches of lighter or darker skin. The condition occurs when parasites remain in the skin after the internal infection is treated.
PKDL can develop anywhere from a few months to several years after completing treatment for visceral leishmaniasis. The timing varies by region and individual factors. In East Africa, PKDL often appears within 6 months to 1 year, while in India it may take longer to develop.
PKDL is not directly contagious from person to person through casual contact. However, people with active PKDL can serve as a reservoir for parasites that sandflies can pick up and spread to others. Preventing sandfly bites helps stop transmission in endemic areas.
PKDL typically causes patches or spots of skin that are lighter or darker than normal skin tone. The changes often appear on the face, especially around the mouth and nose, but can also affect the arms and trunk. Some people develop small bumps or nodules rather than flat patches.
Blood tests can detect antibodies to Leishmania parasites, which suggests current or past infection. The Leishmania antibody test helps support a PKDL diagnosis. However, skin samples are usually needed to confirm parasites are present in the affected skin areas.
Treatment involves antiparasitic medications that target Leishmania parasites. Common options include miltefosine, amphotericin B, and paromomycin. Treatment courses often last several weeks to months and require close monitoring by infectious disease specialists.
Some cases may resolve without treatment, but this can take many years and is unpredictable. Untreated PKDL can persist and serve as a source of infection for others in endemic areas. Treatment helps clear the infection faster and reduces transmission risk.
Anyone who has had visceral leishmaniasis can potentially develop PKDL. Risk is highest in people from East Africa and the Indian subcontinent, where specific parasite species are common. Previous infection with visceral leishmaniasis is the primary risk factor.
There is no guaranteed way to prevent PKDL after visceral leishmaniasis treatment. Completing the full treatment course for visceral leishmaniasis may help reduce risk. Regular follow-up care helps detect PKDL early if it does develop.
With proper treatment, many people see improvement in skin changes over time. Some skin discoloration may persist even after successful treatment, though it often fades gradually. Early treatment provides the best chance for skin to return to normal appearance.